Indonesia has transitioned from standard iron-folic acid supplements to multiple micronutrient supplements (MMS) for pregnant women, aiming to reduce infant mortality. By formalizing a national mandate in October 2024 and establishing domestic manufacturing in 2026, the country is creating a sustainable, locally produced supply chain to improve maternal and newborn health.
Indonesia is switching to multiple micronutrient supplements for the 4.8 million women who become pregnant there each year, moving toward evidence-based prenatal care. While iron and folic acid have long been the standard for preventing maternal anemia, the current clinical consensus suggests that a broader spectrum of micronutrients provides superior outcomes for both mother and child.
Clinical Benefits of Multiple Micronutrients
The transition to the United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) formula is rooted in its ability to address complex nutritional deficiencies. Research indicates that among anemic pregnant women, MMS can reduce infant mortality through the first six months of life by 29%.
Transitioning to Domestic Production
Indonesia’s strategy for a sustainable supply chain began in 2020, eventually leading to a formal mandate by the Ministry of Health in October 2024. To bridge the gap during the transition, the government utilized donor-supported imports from Vitamin Angels and Kirk Humanitarian. This phased approach allowed for the continuous provision of supplements to 2.6 million pregnant women while the domestic pharmaceutical infrastructure was being finalized.
Domestic manufacturing commenced in 2026, with the first large-scale shipment scheduled for delivery this week. This shift is designed to mitigate the risks associated with global supply chain volatility and reduce reliance on international procurement timelines. The government utilized an implementation science approach to identify systemic barriers, ensuring that the new domestic products met the rigorous quality standards required for national distribution.
| Milestone | Status | Impact |
|---|---|---|
| National MMS Mandate | Effective Oct 2024 | Standardized care across all provinces |
| Domestic Manufacturing | Operational 2026 | Reduced reliance on imported supplies |
| E-Catalog Listing | 3 Manufacturers listed | Public and commercial market access |
Indonesian Food and Drug Authority Verifies Local MMS Quality
The Indonesian Food and Drug Authority plays a central role in this transition by verifying that all locally manufactured MMS meet international quality benchmarks. Seven manufacturers have successfully obtained Marketing Authorization Numbers, which certify that their products have passed safety, efficacy, and labeling evaluations. Including these products in the National E-Catalog ensures they are readily available for government health programs.
While the Ministry of Health does not mandate it, the adoption of USP verification by at least one local manufacturer provides an additional layer of quality assurance. This certification ensures that the products meet stringent international standards for purity and potency.
Ministry of Health Expects 1.3 Million Bottles of Local MMS
As of this week, the Ministry of Health expects to receive 1.3 million bottles of locally manufactured MMS through the ongoing support of its international partners to bolster the final phase of the transition.
